Tumor resistance to CD8+ T cell-based therapeutic vaccination

Archivum Immunologiae et Therapiae Experimentalis

Volumn 55, Issue 4, 2007, Pages 205-217

  Huang, Yujun ^a,b   Shah, Shivanee ^a   Qiao, Liang ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

CTL; Therapeutic vaccination; Tumor immunotherapy

Indexed keywords

TUMOR VACCINE;

CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; DENDRITIC CELL; HUMAN; IMMUNOREACTIVITY; NONHUMAN; PROPHYLAXIS; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR; TUMOR IMMUNITY; TUMOR RESISTANCE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TREATMENT FAILURE; TUMOR ESCAPE;

EID: 34547929973     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-007-0029-3     Document Type: Review

References (164)

1. Aarts W. M., Schlom J. and Hodge J. W. (2002): Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res., 62, 5770-5777.
2. Aichele P., Brduscha-Riem K., Zinkernagel R. M., Hengartner H. and Pircher H. (1995): T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med., 182, 261-266.
3. Aichele P., Kyburz D., Ohashi P. S., Odermatt B., Zinkernagel R. M., Hengartner H. and Pircher H. (1994): Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl. Acad. Sci. USA, 91, 444-448.
4. Alpan R. S., Zhang M. and Pardee A. B. (1996): Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res., 56, 4358-4361.
5. Appay V., Nixon D. F., Donahoe S. M., Gillespie G. M., Dong T., King A., Ogg G. S., Spiegel H. M., Conlon C., Spina C. A., Havlir D. V., Richman D. D., Waters A., Easterbrook P., McMichael A. J. and Rowland-Jones S. L. (2000): HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med., 192, 63-75.
6. Arcaro A., Gregoire C., Bakker T. R., Baldi L., Jordan M., Goffin L., Boucheron N., Wurm F., van der Merwe P. A., Malissen B. and Luescher I. F. (2001): CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. J. Exp. Med., 194, 1485-1495.
7. Bai X. F., Liu J., Li O., Zheng P. and Liu Y. (2003): Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Invest., 111, 1487-1496.
8. Banchereau J. and Steinman R. M. (1998): Dendritic cells and the control of immunity. Nature, 392, 245-252.
9. Benitez R., Godelaine D., Lopez-Nevot M. A., Brasseur F., Jimenez P., Marchand M., Oliva M. R., van Baren N., Cabrera T., Andry G., Landry C., Ruiz-Cabello F., Boon T. and Garrido F. (1998): Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 52, 520-529.
10. Bicknell D. C., Rowan A. and Bodmer W. F. (1994): Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc. Natl. Acad. Sci. USA, 91, 4751-4755.
11. Bikah G., Pogue-Caley R. R., McHeyzer-Williams L. J. and McHeyzer-Williams M. G. (2000): Regulating T helper cell immunity through antigen responsiveness and calcium entry. Nat. Immunol., 1, 402-412.
12. Blachere N. E., Li Z., Chandawarkar R. Y., Suto R., Jaikaria N. S., Basu S., Udono H. and Srivastava P. K. (1997): Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med., 186, 1315-1322.
13. Blackman M., Kappler J. and Marrack P. (1990): The role of the T cell receptor in positive and negative selection of developing T cells. Science, 248, 1335-1341.
14. Blattman J. N. and Greenberg P. D. (2004): Cancer immunotherapy: a treatment for the masses. Science, 305, 200-520.
15. Bluestone J. A. and Abbas A. K. (2003): Natural versus adaptive regulatory T cells. Nat. Rev. Immunol., 3, 253-257.
16. Bronstein-Sitton N., Cohen-Daniel L., Vaknin I., Ezernitchi A. V., Leshem B., Halabi A., Houri-Hadad Y., Greenbaum E., Zakay-Rones Z., Shapira L. and Baniyash M. (2003): Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat. Immunol., 4, 957-964.
17. Cardozo C. and Kohanski R. A. (1998): Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome". J. Biol. Chem., 273, 16764-16770.
18. Catlett-Falcone R., Landowski T.H., Oshiro M. M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J. L., Nunez G., Dalton W. S. and Jove R. (1999): Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10, 105-115.
19. Chambers C. A., Sullivan T. J., Truong T. and Allison J. P. (1998): Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol., 28, 3137-3143.
20. Chen L., Linsley P. S. and Hellstrom K. E. (1993): Costimulation of T cells for tumor immunity. Immunol. Today, 14, 483-486.
21. Chen M. L., Pittet M. J., Gorelik L., Flavell R. A., Weissleder R., von Boehmer H. and Khazaie K. (2005): Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA, 102, 419-424.
22. Cresswell P. and Howard J. (1999): Antigen recognition. Curr. Opin. Immunol., 11, 61-63.
23. Cromme F. V., Airey J., Heemels M. T., Ploegh H. L., Keating P. J., Stern P. L., Meijer C. J. and Walboomers J. M. (1994): Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179, 335-340.
24. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L. and Zou W. (2004): Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 10, 942-949.
25. Curtsinger J. M., Lins D. C. and Mescher M. F. (2003): Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med., 197, 1141-1151.
26. Deeths M. J., Kedl R. M. and Mescher M. F. (1999): CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol., 163, 102-110.
27. den Boer A. T., Diehl L., van Mierlo G. J., van der Voort E. I., Fransen M. F., Krimpenfort P., Melief C. J., Offringa R. and Toes R. E. (2001): Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol., 167, 2522-2528.
28. Dissemond J., Goette P., Moers J., Lindeke A., Goos M., Ferrone S. and Wagner S. N. (2003): Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res., 13, 371-377.
29. Dittmer U., He H., Messer R. J., Schimmer S., Olbrich A. R., Ohlen C., Greenberg P. D., Stromnes I. M., Iwashiro M., Sakaguchi S., Evans L. H., Peterson K. E., Yang G. and Hasenkrug K. J. (2004): Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity, 20, 293-303.
30. Doyle A., Martin W. J., Funa K., Gazdar A., Carney D., Martin S. E., Linnoila I., Cuttitta F., Mulshine J., Bunn P. and Minna J. (1985): Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J. Exp. Med., 161, 1135-1151.
31. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D. and Mulligan R. C. (1993): Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90, 3539-3543.
32. Driscoll J., Brown M. G., Finley D. and Monaco J. J. (1993): MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature, 365, 262-264.
33. Dunn G. P., Bruce A. T., Ikeda H., Old L. J. and Schreiber R. D. (2002): Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
34. Fuller C. L., Ravichandran K. S. and Braciale V. L. (1999): Phosphatidylinositol 3-kinase-dependent and -independent cytolytic effector functions. J. Immunol., 162, 6337-6340.
35. Gaczynska M., Rock K. L. and Goldberg A. L. (1993): Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature, 365, 264-267.
36. Gallegos A. M. and Bevan M. J. (2004): Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J. Exp. Med., 200, 1039-1049.
37. Garza K. M., Chan S. M., Suri R., Nguyen L. T., Odermatt B., Schoenberger S. P. and Ohashi P. S. (2000): Role of antigen-presenting cells in mediating tolerance and autoimmunity. J. Exp. Med., 191, 2021-2027.
38. Germain R. N. and Margulies D. H. (1993): The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol., 11, 403-450.
39. Goepfert P. A., Bansal A., Edwards B. H., Ritter G. D. Jr., Tellez I., McPherson S. A., Sabbaj S. and Mulligan M. J. (2000): A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J. Virol., 74, 10249-10255.
40. Greiner J. W., Zeytin H., Anver M. R. and Schlom J. (2002): Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res., 62, 6944-6951.
41. Groettrup M., Khan S., Schwarz K. and Schmidtke G. (2001): Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie, 83, 367-372.
42. Gruener N. H., Lechner F., Jung M. C., Diepolder H., Gerlach T., Lauer G., Walker B., Sullivan J., Phillips R., Pape G. R. and Klenerman P. (2001): Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol., 75, 5550-5558.
43. Guillaume S., Tuosto L., Tanchot C., Di Bartolo V., Acuto O. and Rocha B. (2003): Proximal changes in signal transduction that modify CD8+ T cell responsiveness in vivo. Eur. J. Immunol., 33, 2551-2556.
44. Gurunathan S., Klinman D. M. and Seder R. A. (2000): DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol., 18, 927-974.
45. Hanson H. L., Donermeyer D. L., Ikeda H., White J. M., Shankaran V., Old L. J., Shiku H., Schreiber R. D. and Allen P. M. (2000): Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity, 13, 265-276.
46. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J. V., Steinman R. M. and Nussenzweig M. C. (2001): Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med., 194, 769-779.
47. Heath W. R. and Carbone F. R. (2001): Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol., 19, 47-64.
48. Hermans I. F., Daish A., Yang J., Ritchie D. S. and Ronchese F. (1998): Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res., 58, 3909-3917.
49. Hernandez J., Aung S., Redmond W. L. and Sherman L. A. (2001): Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med., 194, 707-717.
50. Hodge J. W., Poole D. J., Aarts W. M., Gomez Yafal A., Gritz L. and Schlom J. (2003): Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res., 63, 7942-7949.
51. Hodi F. S., Mihm M. C., Soiffer R. J., Haluska F. G., Butler M., Seiden M. V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M. T., Shankar S., Chen T. C., Korman A., Allison J. P. and Dranoff G. (2003): Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA, 100, 4712-4717.
52. Hori S., Nomura T. and Sakaguchi S. (2003): Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057-1061.
53. Huang Y., Fayad R., Smock A., Ullrich A. M. and Qiao L. (2005): Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res., 65, 6990-6999.
54. Huang Y., Obholzer N., Fayad R. and Qiao L. (2005): Turning on/off tumor-specific CTL response during progressive tumor growth. J. Immunol., 175, 3110-3116.
55. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H. and Fujii H. (2003): Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res., 9, 4404-4408.
56. Ikeda H., Ohta N., Furukawa K., Miyazaki H., Wang L., Kuribayashi K., Old L. J. and Shiku H. (1997): Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA, 94, 6375-6379.
57. Iwasaki A. and Medzhitov R. (2004): Toll-like receptor control of the adaptive immune responses. Nat. Immunol., 5, 987-995.
58. Kaech S. M., Hemby S., Kersh E. and Ahmed R. (2002): Molecular and functional profiling of memory CD8 T cell differentiation. Cell, 111, 837-851.
59. Kagi D., Odermatt B., Ohashi P. S., Zinkernagel R. M. and Hengartner H. (1996): Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J. Exp. Med., 183, 2143-2152.
60. Kagi D., Seiler P., Pavlovic J., Ledermann B., Burki K., Zinkernagel R. M. and Hengartner H. (1995): The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol., 25, 3256-3262.
61. Kane L. P., Lin J. and Weiss A. (2000): Signal transduction by the TCR for antigen. Curr. Opin. Immunol., 12, 242-249.
62. Kass E., Panicali D. L., Mazzara G., Schlom J. and Greiner J. W. (2001): Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res., 61, 206-214.
63. Kass E., Schlom J., Thompson J., Guadagni F., Graziano P. and Greiner J. W. (1999): Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res., 59, 676-683.
64. Klebanoff C. A., Finkelstein S. E., Surman D. R., Lichtman M. K., Gattinoni L., Theoret M. R., Grewal N., Spiess P. J., Antony P. A., Palmer D. C., Tagaya Y., Rosenberg S. A., Waldmann T. A. and Restifo N. P. (2004): IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA, 101, 1969-1974.
65. Ko K., Yamazaki S., Nakamura K., Nishioka T., Hirota K., Yamaguchi T., Shimizu J., Nomura T., Chiba T. and Sakaguchi S. (2005): Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med., 202, 885-891.
66. Koneru M., Schaer D., Monu N., Ayala A. and Frey A. B. (2005): Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J. Immunol., 174, 1830-1840.
67. Kostense S., Ogg G. S., Manting E. H., Gillespie G., Joling J., Vandenberghe K., Veenhof E. Z., van Baarle D., Jurriaans S., Klein M. R. and Miedema F. (2001): High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur. J. Immunol., 31, 677-686.
68. Kurts C., Sutherland R. M., Davey G., Li M., Lew A. M., Blanas E., Carbone F. R., Miller J. F. and Heath W. R. (1999): CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA, 96, 12703-12707.
69. Kyburz D., Aichele P., Speiser D. E., Hengartner H., Zinkernagel R. M. and Pircher H. (1993): T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol., 23, 1956-1962.
70. Lanzavecchia A. and Sallusto F. (2002): Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol., 2, 982-987.
71. Lee H. M., Timme T. L. and Thompson T. C. (2000): Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res., 60, 1927-1933.
72. Lee P. P., Yee C., Savage P. A., Fong L., Brockstedt D., Weber J. S., Johnson D., Swetter S., Thompson J., Greenberg P. D., Roederer M. and Davis M. M. (1999): Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5, 677-685.
73. Lefrancois L. (2002): Dual personality of memory T cells. Trends Immunol., 23, 226-228.
74. Lieberman J., Shankar P., Manjunath N. and Andersson J. (2001): Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood, 98, 1667-1677.
75. Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S. and Linehan D. C. (2002): Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol., 169, 2756-2761.
76. Lou Y., Vitalis T. Z., Basha G., Cai B., Chen S. S., Choi K. B., Jeffries A. P., Elliott W. M., Atkins D., Seliger B. and Jefferies W. A. (2005): Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res., 65, 7926-7933.
77. Maloy K. J. and Powrie F. (2001): Regulatory T cells in the control of immune pathology. Nat. Immunol., 2, 816-822.
78. Marincola F. M., Jaffee E. M., Hicklin D. J. and Ferrone S. (2000): Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74, 181-273.
79. McConkey D. J., Greene G. and Pettaway C. A. (1996): Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56, 5594-5599.
80. Melero I., Singhal M. C., McGowan P., Haugen H. S., Blake J., Hellstrom K. E., Yang G., Clegg C. H. and Chen L. (1997): Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol., 71, 3998-4004.
81. Mizoguchi H., O'Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W. and Ochoa A. C. (1992): Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science, 258, 1795-1798.
82. Morel S., Levy F., Burlet-Schiltz O., Brasseur F., Probst-Kepper M., Peitrequin A. L., Monsarrat B., Van Velthoven R., Cerottini J. C., Boon T., Gairin J. E. and Van den Eynde B. J. (2000): Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity, 12, 107-117.
83. Murphy A., Westwood J. A., Teng M. W., Moeller M., Darcy P. K. and Kershaw M. H. (2005): Gene modification strategies to induce tumor immunity. Immunity, 22, 403-414.
84. Nair S. K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J. S., Vieweg J. and Gilboa E. (2000): Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med., 6, 1011-1017.
85. Nair S. K., Hull S., Coleman D., Gilboa E., Lyerly H. K. and Morse M. A. (1999): Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer, 82, 121-124.
86. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J. L., Vivier E., Anderson P. and Kiessling R. (1993): Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53, 5610-5612.
87. Nanda N. K. and Sercarz E. E. (1995): Induction of anti-self-immunity to cure cancer. Cell, 82, 13-17.
88. Nesic D., Jhaver K. G. and Vukmanovic S. (1997): The role of protein kinase C in CD8+ T lymphocyte effector responses. J. Immunol., 159, 582-590.
89. Nguyen L. T., Elford A. R., Murakami K., Garza K. M., Schoenberger S. P., Odermatt B., Speiser D. E. and Ohashi P. S. (2002): Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med., 195, 423-435.
90. Niethammer A. G., Primus F. J., Xiang R., Dolman C. S., Ruehlmann J. M., Ba Y., Gillies S. D. and Reisfeld R. A. (2001): An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine, 20, 421-429.
91. Norbury C. C., Basta S., Donohue K. B., Tscharke D. C., Princiotta M. F., Berglund P., Gibbs J., Bennink J. R. and Yewdell J. W. (2004): CD8+ T cell cross-priming via transfer of proteasome substrates. Science, 304, 1318-1321.
92. Nossal G. J. (1994): Negative selection of lymphocytes. Cell, 76, 229-239.
93. Ochsenbein A. F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H. and Zinkernagel R. M. (1999): Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA, 96, 2233-2238.
94. Ohashi P. S., Oehen S., Buerki K., Pircher H., Ohashi C. T., Odermatt B., Malissen B., Zinkernagel R. M. and Hengartner H. (1991): Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell, 65, 305-317.
95. Ohlen C., Kalos M., Cheng L. E., Shur A. C., Hong D. J., Carson B. D., Kokot N. C., Lerner C. G., Sather B. D., Huseby E. S. and Greenberg P. D. (2002): CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med., 195, 1407-1418.
96. Ohnmacht G. A., Wang E., Mocellin S., Abati A., Filie A., Fetsch P., Riker A. I., Kammula U. S., Rosenberg S. A. and Marincola F. M. (2001): Short-term kinetics of tumor antigen expression in response to vaccination. J. Immunol., 167, 1809-1820.
97. Ormandy L. A., Hillemann T., Wedemeyer H., Manns M. P., Greten T. F. and Korangy F. (2005): Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res., 65, 2457-2464.
98. Otten G. R. and Germain R. N. (1991): Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science, 251, 1228-1231.
99. Overwijk W. W., Theoret M. R., Finkelstein S. E., Surman D. R., de Jong L. A., Vyth-Dreese F. A., Dellemijn T. A., Antony P. A., Spiess P. J., Palmer D. C., Heimann D. M., Klebanoff C. A., Yu Z., Hwang L. N., Feigenbaum L., Kruisbeek A. M., Rosenberg S. A. and Restifo N. P. (2003): Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med., 198, 569-580.
100. Pamer E. and Cresswell P. (1998): Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol., 16, 323-358.
101. Pardoll D. (2003): Does the immune system see tumors as foreign or self? Annu. Rev. Immunol., 21, 807-839.
102. Pasare C. and Medzhitov R. (2003): Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science, 299, 1033-1036.
103. Pasare C. and Medzhitov R. (2004) Toll-dependent control mechanisms of CD4 T cell activation. Immunity, 21, 733-741.
104. Perez V. L., Van Parijs L., Biuckians A., Zheng X. X., Strom T. B. and Abbas A. K. (1997): Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity, 6, 411-417.
105. Prevost-Blondel A., Zimmermann C., Stemmer C., Kulmburg P., Rosenthal F. M. and Pircher H. (1998): Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol., 161, 2187-2194.
106. Qian D. and Weiss A. (1997): T cell antigen receptor signal transduction. Curr. Opin. Cell Biol., 9, 205-212.
107. Redmond W. L. and Sherman L. A. (2005): Peripheral tolerance of CD8 T lymphocytes. Immunity, 22, 275-284.
108. Rocha B., Grandien A. and Freitas A. A. (1995): Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J. Exp. Med., 181, 993-1003.
109. Rock K. L. and Goldberg A. L. (1999): Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol., 17, 739-779.
110. Rosenberg S. A. (2001): Progress in human tumour immunology and immunotherapy. Nature, 411, 380-384.
111. Rosenberg S. A., Yang J. C. and Restifo N. P. (2004): Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 10, 909-915.
112. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Dudley M. E., Schwarz S. L., Spiess P. J., Wunderlich J. R., Parkhurst M. R., Kawakami Y., Seipp C. A., Einhorn J. H. and White D. E. (1998): Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4, 321-327.
113. Sakaguchi S. (2004): Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol., 22, 531-562.
114. Sakaguchi S., Sakaguchi N., Asano M., Itoh M. and Toda M. (1995): Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 155, 1151-1164.
115. Sanchez-Perez L., Kottke T., Diaz R. M., Ahmed A., Thompson J., Chong H., Melcher A., Holmen S., Daniels G. and Vile R. G. (2005): Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res., 65, 2009-2017.
116. Sasada T., Kimura M., Yoshida Y., Kanai M. and Takabayashi A. (2003): CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 98, 1089-1899.
117. Schoenberger S. P., Toes R. E., van der Voort E. I., Offringa R. and Melief C. J. (1998): T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483.
118. Schuurhuis D. H., Laban S., Toes R. E., Ricciardi-Castagnoli P., Kleijmeer M. J., van der Voort E. I., Rea D., Offringa R., Geuze H. J., Melief C. J. and Ossendorp F. (2000): Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med., 192, 145-150.
119. Seliger B., Hohne A., Knuth A., Bernhard H., Ehring B., Tampe R. and Huber C. (1996): Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res., 2, 1427-1433.
120. Seliger B., Maeurer M. J. and Ferrone S. (2000): Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21, 455-464.
121. Setiadi A. F., David M. D., Chen S. S., Hiscott J. and Jefferies W. A. (2005): Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res., 65, 7485-7492.
122. Shankar P., Russo M., Harnisch B., Patterson M., Skolnik P. and Lieberman J. (2000): Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood, 96, 3094-3101.
123. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J. and Schreiber R. D. (2001): IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
124. Shevach E. M. (2002): CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol., 2, 389-400.
125. Shimizu J., Yamazaki S., Takahashi T., Ishida Y. and Sakaguchi S. (2002): Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol., 3, 135-142.
126. Shrikant P., Khoruts A. and Mescher M. F. (1999): CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity, 11, 483-493.
127. Shrikant P. and Mescher M. F. (1999): Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol., 162, 2858-2866.
128. Slansky J. E., Rattis F. M., Boyd L. F., Fahmy T., Jaffee E. M., Schneck J. P., Margulies D. H. and Pardoll D. M. (2000): Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity, 13, 529-538.
129. Sogn J. A. (1998): Tumor immunology: the glass is half full. Immunity, 9, 757-763.
130. Stevenson F. K., Ottensmeier C. H., Johnson P., Zhu D., Buchan S. L., McCann K. J., Roddick J. S., King A. T., McNicholl F., Savelyeva N. and Rice J. (2004): DNA vaccines to attack cancer. Proc. Natl. Acad. Sci. USA, 101 (suppl. 2), 14646-14652.
131. Sutmuller R. P., van Duivenvoorde L. M., van Elsas A., Schumacher T. N., Wildenberg M. E., Allison J. P., Toes R. E., Offringa R. and Melief C. J. (2001): Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med., 194, 823-832.
132. Tanaka K. and Chiba T. (1998): The proteasome: a protein-destroying machine. Genes Cells, 3, 499-510.
133. Tanaka K. and Kasahara M. (1998): The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol. Rev., 163, 161-176.
134. Tanchot C., Guillaume S., Delon J., Bourgeois C., Franzke A., Sarukhan A., Trautmann A. and Rocha B. (1998): Modifications of CD8+ T cell function during in vivo memory or tolerance induction. Immunity, 8, 581-590.
135. Timmerman J. M. and Levy R. (1999): Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med., 50, 507-529.
136. Trapani J. A. and Smyth M. J. (2002): Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol., 2, 735-747.
137. Trimble L. A., Shankar P., Patterson M., Daily J. P. and Lieberman J. (2000): Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J. Virol., 74, 7320-7330.
138. Uyttenhove C., Maryanski J. and Boon T. (1983): Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med., 157, 1040-1052.
139. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A. and Boon T. (1991): A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647.
140. Van Parijs L. and Abbas A. K. (1998): Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science, 280, 243-248.
141. Vezys V., Olson S. and Lefrancois L. (2000): Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity, 12, 505-514.
142. Viguier M., Lemaitre F., Verola O., Cho M. S., Gorochov G., Dubertret L., Bachelez H., Kourilsky P. and Ferradini L. (2004): Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol., 173, 1444-1453.
143. Vogel T. U., Allen T. M., Altman J. D. and Watkins D. I. (2001): Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection. J. Virol., 75, 2458-2461.
144. Walunas T. L., Lenschow D. J., Bakker C. Y., Linsley P. S., Freeman G. J., Green J. M., Thompson C. B. and Bluestone J. A. (1994): CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1, 405-413.
145. Wang H. Y., Lee D. A., Peng G., Guo Z., Li Y., Kiniwa Y., Shevach E. M. and Wang R. F. (2004): Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity, 20, 107-118.
146. Wherry E. J., Blattman J. N., Murali-Krishna K., van der Most R. and Ahmed R. (2003): Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol., 77, 4911-4927.
147. Wick M., Dubey P., Koeppen H., Siegel C. T., Fields P. E., Chen L., Bluestone J. A. and Schreiber H. (1997): Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med., 186, 229-238.
148. Wilcox R. A., Flies D. B., Zhu G., Johnson A. J., Tamada K., Chapoval A. I., Strome S. E., Pease L. R. and Chen L. (2002): Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest., 109, 651-659.
149. Wilcox R. A., Tamada K., Flies D. B., Zhu G., Chapoval A. I., Blazar B. R., Kast W. M. and Chen L. (2004): Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood, 103, 177-184.
150. Willimsky G. and Blankenstein T. (2005): Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature, 437, 141-146.
151. Wolf A. M., Wolf D., Steurer M., Gastl G., Gunsilius E. and Grubeck-Loebenstein B. (2003): Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res., 9, 606-612.
152. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Buschenfelde K. H. and Beach D. (1995): A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281-1284.
153. Wolkers M. C., Brouwenstijn N., Bakker A. H., Toebes M. and Schumacher T. N. (2004): Antigen bias in T cell cross-priming. Science, 304, 1314-1317.
154. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R. and June C. H. (2001): Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res., 61, 4766-4772.
155. Xiang R., Primus F. J., Ruehlmann J. M., Niethammer A. G., Silletti S., Lode H. N., Dolman C. S., Gillies S. D. and Reisfeld R. A. (2001): A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J. Immunol., 167, 4560-4565.
156. Xiang R., Silletti S., Lode H. N., Dolman C. S., Ruehlmann J. M., Niethammer A. G., Pertl U., Gillies S. D., Primus F. J. and Reisfeld R. A. (2001): Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin. Cancer Res., 7, 856s-864s.
157. Xiong Y., Luscher M. A., Altman J. D., Hulsey M., Robinson H. L., Ostrowski M., Barber B. H. and MacDonald K. S. (2001): Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J. Virol., 75, 3028-3033.
158. Yang Y., Huang C. T., Huang X. and Pardoll D. M. (2004): Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol., 5, 508-515.
159. Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E. and Greenberg P. D. (2002): Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA, 99, 16168-16173.
160. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H. and Fu Y. X. (2005): Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med., 201, 779-791.
161. Zajac A. J., Blattman J. N., Murali-Krishna K., Sourdive D. J., Suresh M., Altman J. D. and Ahmed R. (1998): Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med., 188, 2205-2213.
162. Zamoyska R. (1998): CD4 and CD8: modulators of T-cell receptor recognition of antigen and of immune responses? Curr. Opin. Immunol., 10, 82-87.
163. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., Rimoldi D., Guillaume P., Meidenbauer N., Mackensen A., Rufer N., Lubenow N., Speiser D., Cerottini J. C., Romero P. and Pittet M. J. (2004): Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res., 64, 2865-2873.
164. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G. and Amigorena S. (1998): Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med., 4, 594-600.